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ABSTRACT 
 
A summary is provided of presentations and discussions from the NASA 
Radiation Biomarker Workshop held September 27-28, 2007, at NASA Ames 
Research Center in Mountain View, California.  Invited speakers were 
distinguished scientists representing key sectors of the radiation research 
community.  Speakers addressed recent developments in the biomarker and 
biotechnology fields that may provide new opportunities for health-related 
assessment of radiation-exposed individuals, including for long-duration space 
travel.  Topics discussed include the space radiation environment, biomarkers of 
radiation sensitivity and individual susceptibility, molecular signatures of low-dose 
responses, multivariate analysis of gene expression, biomarkers in biodefense, 
biomarkers in radiation oncology, biomarkers and triage following large-scale 
radiological incidents, integrated and multiple biomarker approaches, advances 
in whole-genome tiling arrays, advances in mass-spectrometry proteomics, 
radiation biodosimetry for estimation of cancer risk in a rat skin model, and 
confounding factors.  Summary conclusions are provided at the end of the report. 
 
INTRODUCTION 
 
On September 27-28, 2007, the NASA Ames Research Center hosted a 
workshop on Radiation Biomarkers with support and participation from the Space 
Radiation Project Element (SRPE) of the Human Research Program, NASA 
Johnson Space Center.  The overall goal of the workshop was to provide an 
update of the radiation biomarker research across key sectors of the radiation 
research community—academia, clinical medicine, DOE labs, DOD labs, and 
NASA, with an eye toward potential future applications in space.  This was a first 
in a series of workshops to provide periodic updates and help define research 
needs for future applications on long-duration human space missions. 
 
With the possible exception of cataracts (1), there are presently no direct human 
data available from space-type radiation for any of the radiation-induced risks 
considered of highest priority by NASA for long duration human space travel, i.e., 
carcinogenesis, acute and late CNS risks, chronic and degenerative tissue risks, 
and acute radiation risks (2).  Although information exists from Earth-based 
studies sufficient to recommend crew exposure limits and spacecraft design 
requirements for missions in low Earth orbit, there is insufficient knowledge of the 
health effects of space radiation to provide recommendations on crew exposure 
limits and design requirements for extended lunar and Mars missions (3). A 
major focus of the NASA space radiation effort is basic and fundamental 
research to expand the knowledge base and reduce the uncertainty inherent in 
current exposure limits and design requirements.  At present, this includes a 
large number of radiobiological research projects mostly performed by peer 
reviewed principal investigators in academia using accelerator-based simulated 
space radiation at the NASA Space Radiation Laboratory, Brookhaven, NY.  
Biomarkers (biodosimetry) is embedded within the radiobiology research.  It is 
anticipated that information on the mechanisms and processes involved in space 
radiation damage and repair will reveal specific indicators of space radiation 
exposure.  The NASA Strategic Program Plan for Space Radiation Health 
Research (3) indicates that biomarkers/biodosimetry will be specifically pursued 
during Phase 3 (2010 - 2023). 
 
Biomarkers to assess radiation response (and dose) in astronauts have been 
used since the early 1960’s.  The first such assessments were made by Bender 
et al. (4,5) who measured dicentric chromosome aberrations in peripheral blood 
lymphocytes of crewmembers of Gemini-3 and Gemini-11.  These flights lasted 
only 5 h and 3 d, respectively, and no significant increase in chromosome 
damage was observed when comparing pre-flight and post-flight samples.  More 
recently, a substantial database has emerged using various cytogenetic 
methods, including fluorescence in-situ hybridization (FISH) techniques, to 
evaluate pre- and post-mission blood lymphocyte samples from crewmembers on 
Mir and ISS (6-9).  Results indicate that radiation dose accumulated over a 
period of a few months or more can induce a measurable increase in the yield of 
chromosome damage.  However, shorter missions of a few weeks or less appear 
to be below the detection limit for cytogenetic effects. 
 
Advances in genomics, proteomics, and experimental low-dose radiobiology, are 
providing new opportunities for radiation biomarker development.  Given the 
lead-time required for biomarker development and NASA’s plan to return humans 
to the Moon by 2019 and onward to Mars by 2030, it is important to discuss the 
potential utility of biomarkers in space and the extent to which uncertainties in 
space radiation risk assessment could perhaps be reduced by biomarker-based 
research studies.  Further discussions should include how the large number of 
animal radiobiology studies supported by several federal agencies could partner 
with human biomarker studies to facilitate cross-species extrapolation, and 
ultimately extrapolation to humans. 
 
THE SPACE RADIATION ENVIRONMENT 
 
The radiation environment in space is complex.  Radiation includes charged 
particles such as hydrogen and iron, and a myriad of secondary radiation 
including neutrons produced by charged particle interactions with materials (e.g., 
spacecraft, astronauts, the surface of the Moon, etc.).  During periods of low-
solar activity, the major contributor to dose in deep space or on the lunar surface 
is galactic cosmic radiation (GCR), which is composed primarily of high-energy 
protons (in the GeV range).  GCR also includes heavier charged particles 
ranging from helium to iron nuclei.  During periods of high-solar activity 
(approximately 11 year cycle) the probability for a significant solar particle event 
(SPE) is elevated.  A large SPE can release a very high flux of charged particle 
radiation---about 98% consists of protons, which are typically less than ~150 
MeV. 
 
High-energy GCR radiation is very penetrating and therefore difficult to shield, 
i.e., a large fraction of the charged particles are in the GeV/nucleon range (10).  
For example, a 1 GeV proton has a range of 324 cm in water and a 1 
GeV/nucleon 56Fe nucleus has a range of 27 cm water.  In contrast, solar protons 
typically penetrate less than about 10 cm in water, and the vast majority 
penetrate less than 1 cm in water, barely enough to penetrate a lunar 
extravehicular activity (EVA) spacesuit (11).  In addition to their differences in 
penetration power, the high-energy particles from GCR produce more secondary 
radiation via spallation reactions in materials.  In some cases, these secondary 
radiations have larger relative biological effectiveness (RBE) than the primary 
radiations.  Hence, shielding of GCR radiation poses a challenge for long-term 
space travel as well as for human habitation of a base on the Moon. 
 
During non-SPE solar minimum conditions, the dose-equivalent rate in 
interplanetary space is estimated to be in the 0.5 to 1.4 Sv/y range (12).  Due to 
shielding by the Moon, the dose-equivalent rate on the lunar surface is estimated 
to be less than in interplanetary space.  However, lunar surface dose modeling is 
complicated due to secondary radiation (e.g., neutron) production in the lunar 
regolith.  It is estimated that a 6-mo stay on the Moon would result in exposure to 
about 0.15 Sv (13).  A 2.5-y roundtrip to Mars may result in an integrated dose-
equivalent on the order of 1 Sv (12).  These dose estimates (which assume no 
significant SPEs during the mission) are not expected to result in significant 
short-term risk, but they may increase the long-term stochastic health risks that 
are associated with radiation exposure.  Because these doses are primarily from 
GCR, they are unlikely to be substantially reduced by shielding. 
 
In contrast, SPEs pose a different challenge.  Although protons from SPEs are of 
much lower energy than those from GCR (and therefore can be more readily 
shielded), they pose an acute health risk for astronauts who are exposed during 
extravehicular activity (EVA).  For example, if an astronaut were participating in 
an EVA on the Moon during the August 1972 SPE and received the full radiation 
from that event, the doses are calculated to be 40 Sv to the skin, 5 Sv to the 
yellow marrow, and 1.7 Sv to the red marrow (11).  These doses would have 
greatly exceeded the current 30-day dose limits established for LEO of 1.5 Sv for 
skin and 0.25 Sv for marrow.  The dose rates during a large SPE range from 
ambient to ~0.5 Sv/h for marrow and to more than 10 Sv/h for skin.  Although 
these dose rates are considered to be high for most radiation protection 
conditions, they are not considered radiobiologically acute (defined as 1 Gy/min), 
and are expected to have an effectiveness higher than chronic, but lower than 
acute.  Thus, the SPE radiation would have the additional complexity of 
intermediate and varying dose rate and response. 
 INDIVIDUAL SUSCEPTIBILITY 
 
Dr. William Morgan (University of Maryland) addressed challenges associated 
with biomarkers of radiation sensitivity and individual susceptibility.  He noted 
that when attempting to identify individuals at risk for developing radiation-
induced cancer, one must consider the genetic complexities involved in 
carcinogenesis.  Thus, it may be important to identify the genes responsible for 
initiation, promotion and progression of cancer.  However, the actual variants 
contributing to such complex diseases are unknown.  The most common type of 
variation in the genome is the single nucleotide polymorphism (SNP). SNPs 
occur once in every 300-500 nucleotides (14).  SNPs give rise to individual gene 
variants that alter susceptibility to common diseases.  Consequently, mapping 
complex traits requires determining which of the myriad of SNP’s influence 
disease risk.  Rapidly developing technologies will facilitate identification of risk-
related SNPs.  However, any genetic variation may be complicated by gene-gene 
and/or gene-environment interactions.  Each SNP is a rare event.  Therefore, 
studies of a very large human population are required to identify SNPs that may 
be useful markers of disease susceptibility. 
 
Nevertheless, there is little question of the role of DNA repair in ameliorating the 
effects of radiation-induced DNA damage and minimizing the incidence of 
cancer.  Many of the cancer genes identified in family studies have a role in DNA 
replication and/or repair.  The loss of function for many DNA repair or repair-
related genes is incompatible with normal development and often results in 
embryonic lethality.  A more challenging question is the extent to which any 
alteration in the ability to repair damaged DNA contributes to the sporadic 
incidence of cancer.  Given that most individuals show extensive sequence 
variation in their DNA repair genes, it is likely that susceptibility will vary among 
individuals, depending on the particular combination of inherited alleles. 
 
Evidence for the importance of a moderate reduction in DNA repair is 
accumulating from animal models. BALB/c mice are sensitive to radiation-
induced mammary tumors.  Genetic linkage analysis indicates that this sensitivity 
is associated with allelic variation in the catalytic subunit of DNA-PKcs, a gene 
involved in the non-homologous enjoining pathway (15).  In addition, a number of 
transgenic knock-out mouse models have provided direct evidence for a 
significant role of DNA repair related gene function in carcinogenesis. For 
example, mice that are heterozygous for a mutation in ATM, the gene involved in 
the disease ataxia-telangiectasia (AT), have heightened susceptibility to cancer. 
Such mice are more sensitive to high -dose ionizing radiation than are their wild-
type counterparts (16).  It is estimated that ~1% of the human population is 
heterozygous for ATM.  Data in mice suggest that ATM heterozygotes are 
susceptible to radiation-related cancer. 
 
However, a number of in vitro experiments using cultured cells from AT 
heterozygotes have failed to demonstrate enhanced sensitivity to ionizing 
radiation, particularly at low doses (17). Most techniques are able to detect a shift 
in the average response of AT heterozygote cells, compared with normal cells, 
but with considerable overlap between the two groups.  Although somewhat 
controversial, one assay that appears to provide excellent discrimination involves 
x-irradiating cells in G2 and quantifying radiation-induced cytogenetic damage 
(18).  Furthermore, haplo-insufficiency is only one factor that may induce 
susceptibility to radiation exposure.  Allelic imbalance in gene expression levels 
can be caused by other factors such as cis acting regulatory polymorphisms in 
coding, intronic or regulatory sequences, as well as by differential DNA 
methylation or histone acetylation.  In addition to genetic factors, non-genetic 
factors might possibly add to the complexity of radiation susceptibility.  Such 
factors include lifestyle, diet, smoking and reproductive history. 
 
While it is likely that one day it will be possible to identify radiation sensitive / 
resistant individuals, such radiation responses may be normally distributed within 
the population.  In adequately identifying such a phenotype one must then 
consider how radiation responses are modulated by given genetic and epigenetic 
considerations as well as environmental impacts, but also a host of social, 
ethical, and legal considerations. 
 
MOLECULAR SIGNATURES OF LOW-DOSE RESPONSES 
 As summarized by Dr. Andrew J. Wyrobek (Lawrence Berkeley National 
Laboratory), systems biology approaches have been employed to evaluate 
cellular responses to low-dose radiation using genomic gene-expression 
technologies and bioinformatics tools.  The objective of radiation system biology 
approaches is to improve the knowledge of early cellular responses to low-dose 
radiation and to reduce the uncertainties of assessing genetic health risk at low-
dose levels (19,20).  The early transcriptome profiling studies underscore the 
complexity of gene-expression phenotypes and response pathways that are 
modulated in cells and tissues after low doses. Complex gene networks and 
pathways have been identified for low-dose exposures (21) and for cellular 
protection mechanisms against radiation-induced cytogenetic damage (22). 
Bioinformatics analyses have identified similar gene networks after low-dose 
exposures in both mouse and human models, suggesting that there are robust 
low-dose radiation responses across tissues and species. Radiation gene 
expression profiles have also been characterized for the proteome (23). 
 
Low dose effects on cells have been evaluated experimentally using a variety of 
exposure regimens including acute, low dose rate or chronic, and adaptive 
response (AR) exposure regimens. AR regimens are important because they 
show that under certain circumstances and with some variability not yet 
understood, low dose exposure can confer radioprotection against subsequent 
exposures.  Typical AR regimens use a low dose (priming dose) followed some 
hours later by a high dose (challenge dose) to determine whether the priming 
dose conferred protection against damaging effects of the challenge dose.  
Radioadaptive protection has been described for cell killing, DNA damage, 
chromosomal aberrations, cancer latency and other cellular phenomena in a 
variety of biological models, most notably as summarized below. 
 
Transcriptome analyses have been performed in human cell lines irradiated in 
vitro. Analyses of a detailed dose-response curve (1-400 cGy) in human 
lymphoblastoid cells from two unrelated individuals identified a set of ~300 low-
dose responsive genes (1-10cGy), several of which did not have a significant 
dose slope, consistent with plateau-like responses in the low-dose range.  
Bioinformatics analyses suggest that low-dose-responsive gene products are 
associated with cellular homeostasis mechanisms, special signal transduction 
pathways, and various subcellular locations. 
 
Transcriptome analyses of the cytogenetic AR have also been performed in 
human cells.  More than 100 genes were identified whose expression was 
associated with the AR (22). This study provided molecular insights into the 
mechanisms of cellular protection against radiation-induced chromosomal 
damage.  It was hypothesized that the pathways associated with these genes are 
the basis of an AR molecular switch that controls the degree of protection against 
radiation-induced chromosome damage in irradiated cells.  Research is in 
progress to test this molecular switch in mice after whole-body radiation 
exposures. 
 
Baseline gene expression has been evaluated in the tissues of unirradiated mice.  
Baseline transcriptional profiles were characterized for preselected genes 
associated with DNA damage recognition and repair processes among several 
tissues of healthy adult mice (testis, brain, liver, spleen and heart). Significant 
tissue variation was found in the baseline expressions of stress response, 
damage control and DNA repair-associated genes (21). Overall, stress response 
genes exhibited the greatest variation among tissues with the highest expression 
in liver and heart while DNA repair genes exhibited the least variation among 
tissues.  A multitude of factors, including metabolic activity, immunological and 
inflammation status and oxidative damage may affect the expression of stress 
response genes.  Damage control genes associated with cell cycle regulation 
and DNA repair genes generally had the highest expression in testis.  Variations 
in basal expression of DNA damage recognition and repair-associated genes 
among healthy tissues provided the foundation for investigating their differential 
response to genotoxic agents and susceptibility to genetic disease. 
 
Transcriptome analyses have been performed to study the effects of whole body 
radiation on mouse brain tissue.  Cellular functions associated with altered 
transcript profiles were characterized for mouse brain exposed to low-dose in-
vivo gamma irradiation.  Whole-body exposure of male mice to low-LET radiation 
altered the transcript expression in their central nervous system, with distinct 
time- and dose-dependent clusters and identified low-dose unique gene sets 
(24).  Advanced bioinformatics was applied to identify the major gene networks 
and biochemical pathways that were uniquely associated with low-dose versus 
high-dose exposures as well as pathways shared across doses.  Brain irradiation 
modulated the expression patterns of over 1000 genes, of which >800 showed 
more than 1.5-fold variation.  About 30% of genes showed dose-dependent 
variations, including genes exclusively affected by 0.1 Gy.  About 60% of genes 
showed time-dependent variation with more genes affected at 30 min than at 4 h.  
Early changes involved signal transduction, ion regulation and synaptic signaling. 
Later changes involved metabolic functions including myelin and protein 
synthesis.  Low-dose radiation also modulated the expression of genes involved 
in stress response, cell-cycle control and DNA synthesis/repair.  This study 
demonstrated that doses of 0.1 Gy induced changes in gene expression that 
were qualitatively different from those at 2 Gy. The findings suggest that low-
dose irradiation of the brain induces the expression of genes involved in 
protective and reparative functions, while down-modulating genes involved in 
neural signaling activity.  In situ analyses in tissue sections provide important 
validation approaches to assess variations in radiation responses among 
different neuronal cell types (e.g., 25).  Our results support the model that brain 
tissue exposed to low-dose radiation employs unique molecular response 
pathways not observed after high doses, which underscore the problems that will 
be encountered when using high–dose data to infer low-dose mechanisms and to 
assess low-dose CNS radiation risks. 
 
Dr. Wyrobek concluded that systems radiation biology approaches with 
advanced bioinformatics are showing substantial promise for improving the 
molecular understanding of the early cellular responses to low-dose radiation and 
to help to reduce the uncertainty of assessing risk at low-dose levels.  The finding 
of low-dose unique genes and pathways in both human cells and mouse brain 
tissues sets the foundation for identifying risk predictors for genomic instability 
and disease susceptibility in tissues irradiated in vivo. 
 
MULTIVARIATE ANALYSIS OF GENE EXPRESSION 
 
Dr. Nicholas Dainiak (Yale University) presented his work on multivariate analysis 
of cytokine gene expression after low dose radiation exposure.  He concluded 
that while DNA microarray analysis may provide insight into gene function within 
and across biological networks, meaningful data can be generated only when 
studies are appropriately controlled and when the state of a living system is well 
defined.  Parameters that are critical for the study of radiation effects include 
radiation quality, dose, dose rate, cell type and tissue type.  Owing to the 
enormity of the data set, appropriate methods of data analysis must be applied, 
including those that determine inherent grouping (hierarchical cluster analysis or 
HCA and principal component analysis or PCA) and those that define known 
class membership (26).  
 HCA uses the entire data set to extract natural clusters without reducing 
dimensionality of the data.  Consequently, HCA becomes computationally 
unfeasible with very large data sets having an indirect relationship with a 
covariate.  Methods that reduce dimensionality and eliminate non-significant 
information include PCA and projection pursuit (PP).  A disadvantage of PCA is 
that it is unable to determine maximum probability for heteroscedastic (i.e. non-
uniform) uncertainties that may be correlated with each other.  It is difficult for 
PCA to distinguish noise (i.e., spot variation) from systemic variance (i.e., bias in 
the microarray).  Studies with large within-group variance may be better analyzed 
by projection pursuit, a technique that has been used to analyze chemical data 
sets (27,28).  Accordingly, clustering may be revealed when within-group 
variance is large.  
  
Whereas for PCA, latent variables are transformed into space according to the 
singular value decomposition algorithm, PP employs principle component scores 
to obtain sequential maximized chi-square indices.  The resulting PP factors are 
used to generate two candidate planes that are evaluated by the method of 
Posse, and the PP index with the least variance is defined as the new starting 
plane.  The algorithm iterates until the most informative structure is obtained.  
Since PP seeks departure from normality, it is not sensitive to outliers. 
 
Using an in-house PP algorithm and MATLAB and PP functions (Computational 
Statistics Toolbox), scores plots were compared from PCA and PP in microarrays 
prepared from mRNA of human subjects exposed to 0.18-49.00 mSv as a result 
of the Chernobyl Nuclear Power Plant catastrophe.  Improved clustering was 
obtained when PP was used, both for the groups of identified genes and for intra-
cluster variance (29).  Table 1 shows that PP detects the expression of genes in 
seven distinct groupings at 11-13 years after low-dose exposure. 
 
The biological relevance of clusters identified by PP is striking.  For example, IL-
8, MCP-1, TNF-α and IL-10 negatively regulate hematopoietic stem/progenitor 
cell proliferation.  It is possible that such cytokines mediate cytopenias occurring 
after irradiation.  In addition, TNFRSF (Fas) and its cognate ligand are 
overexpressed on the cell surface after irradiation (30,31), an interaction that is 
required for radiation–induced apoptosis in lymphocytes (32).  Furthermore, 
identification of overexpressed ligands (i.e., IL-8 and TNFα) and their respective 
receptors in one or more clusters, suggests that the pathways in which these 
molecules participate, are involved in the biological response to ionizing radiation.  
It is unknown whether a gene in a cluster activates another gene of the cluster 
(i.e., overexpression of the two genes may be independent of each other).  
Regardless, PP has the potential to identify expression profiles that may possibly 
explain biological effects of radiation exposure. 
 
Table 1.  Comparison of clusters from PCA and PP 
 In conclusion, microarray technology has revolutionized genome-scale data 
collection by increasing the throughput of information in a short period of time.  
The plethora of information provided by microarrays must be assessed with tools 
that not only account for inherent noise components but also provide sufficiently 
robust analysis.  The application of new tools such as PP and methods that are 
based on known class membership, may address both of these issues and 
provide structures (i.e., gene clusters) that are more biologically relevant than 
those provided by traditional methods such as HCA and PCA.  Since there is no 
consensus regarding the best method to analyze a multivariate data set, it is 
recommended that microarray data be submitted to public databases where 
information can be reevaluated and interpreted, as new methods for data analysis 
are applied (33). 
 
BIOMARKERS IN BIODEFENSE 
 
Dr. Ken Turteltaub (Lawrence Livermore National Laboratory) discussed their 
extensive work on biodefense biomarkers.  Over the last decade, interest in 
developing biomarkers for use in measuring hazardous exposures, risk from 
such exposures, and for use in early disease diagnosis has grown exponentially.  
New technologies allow rapid high capacity analysis of genes, proteins and most 
recently small molecules.  While significant progress is being made, a number of 
studies have raised issues on intra- and inter-laboratory reproducibility, and the 
influence of confounding factors on the ability to use biomarkers as a diagnostic 
test in the field. 
 
Approximately 6 years ago, LLNL initiated a project to test the feasibility of 
detecting and diagnosing an infectious disease using changes in the levels of 
biomolecules in peripheral blood.  LLNL proposed that the underlying 
biochemistry of an organism changes under the influence of a stressor such as 
an infectious agent.  It was reasoned that these biochemical changes would 
begin as soon as the host cells began interacting with the pathogen and that a 
change in physiology would trigger changes in the levels of molecules residing 
inside cells and body fluids.  Detection of these changes might be used to both 
detect a developing disease early, possibly in the presyndromic or prodromal 
period, and allow more rapid intervention with the result being reduced morbidity 
and mortality.  Thus, a series of studies were conducted in rodents and in human 
samples to assess quantification capabilities of several high throughput 
technologies such as arrays, mass spectrometry, gel electrophoresis, solution-
based multiplexed antibody assays and RT-PCR.  A controlled experiment in 
rodents was conducted to discover which gene transcripts and proteins in plasma 
change in expression when challenged with a virus and when these changes 
would be first detectable following exposure.  This was then explored in an 
apparently healthy human population to determine how variable a set of blood 
gene transcripts would be and how stable they were expressed over time.  
Finally, gene transcript changes and protein levels were measured in several 
human cohorts, including individuals with HIV, rheumatoid arthritis, dialysis 
patients, bacteremia, and in a group of apparently healthy individuals during a 
marathon run.  These groups simulated a series of potentially confounding 
factors such as individual variability, pre-existing conditions, and the effects of 
general physical stress on the levels of protein and nucleic acid transcript levels 
in blood.  All these situations are relevant to potential factors that could influence 
an individual’s response to radiation in space including co-exposure to infectious 
agents, physical stress from living in an extreme environment and individual 
differences in response. 
 
The results in inbred laboratory animals suggest that under laboratory controlled 
conditions it is possible to detect pathological states with biomarkers a few days 
prior to development of overt symptoms.  It is also possible to detect overtly ill 
humans using single biomarkers.  Detection of prodromal disease states were 
much more difficult to impossible to detect or diagnose based on a single 
biomarker.  Use of multiple markers combined into a panel can produce a 
signature that discriminates early pathological states from healthy people in 
some situations. 
 
A variety of factors made discrimination of early pathological states difficult in the 
human studies including sample collection, storage and shipping methods, sites 
of sample collection from the individual, and the method used for quantification.  
Significant changes in blood protein levels were found in the marathon runners 
both during and after the run.  Significant changes were found in mice in gene 
expression depending on whether the blood was collected from the tail vein or by 
retro-orbital bleeding.  Large differences were seen among rheumatoid arthritis 
patients in gene expression patterns.  Thus sample collection, physical stress, 
pre-existing conditions and the method of analysis can impact the levels of 
potential biomarkers found in blood.  It was concluded that use of molecular 
signatures to detect and diagnose disease in the presyndromic and prodromal 
phases of a disease’s pathology is possible but significant attention needs to be 
paid to understanding factors that affect levels of potential markers as well as the 
factors that affect their analysis.  Attention should be placed on finding both sets 
of molecules that are sensitive to the disease state which will likely be sensitive 
to other biological factors as well as ones that are refractory to confounding 
factors (which may be less sensitive to the disease state).  Combination of these 
two groups of markers into panels may provide a signature that would be useful 
in (i) assessing exposure to hazardous environments, (ii) determining risk from 
that exposure, and (iii) diagnosing a developing disease early. 
 
BIOMARKERS IN RADIATION ONCOLOGY 
 
Dr. Srinivasan Vijayakumar, Dr. Andrew Vaughan, and colleagues from the UC 
Davis Medical Center presented the radiation oncology perspective on 
biomarkers.  Advances in the field of radiation treatment of tumors both clinically 
and as regards general radiation effects on living systems require an integrated 
approach that combines studies of basic biological mechanisms, the physics of 
dose deposition and measurement with the assessment of relevant endpoints of 
acute and chronic biological change.  Biological responses have the potential to 
be applied to individual patient treatment. 
 
From the perspective of basic biology the utility of biological markers of radiation 
effects may be viewed in different ways.  The most direct utility of a biological 
marker is one that records the presence of a radiation exposure at some time in 
the past.  Of these, levels of specific gene transcripts or proteins have been 
studied by a number of groups and radiation-responsive genes identified in a 
number of tissues – most commonly circulating cells of the blood.  However such 
studies are complicated by the assumption that the dose to an individual is 
uniform.  Nonuniform dose dramatically increases the complexity of dose 
analysis and thus the ability to predict biological response.  In an effort to gain 
some information on regionally defined irradiation, the response of buccal cavity 
cells was examined in patients undergoing irradiation for head and neck tumors.  
Such cells comprise the inner lining of the mouth and are easily sampled by 
gentle brushing of the mouth cavity and immediate extraction of RNA.  Samples 
were taken from four quadrants (upper/lower, back/front) both before and after 
the first radiation dose of an approximately 30-fraction course.  Such dose to the 
tumor target might peak at around 2 Gy with doses to the sampling positions 
within the buccal mucosa ranging from this dose downward.  The dose to each 
quadrant was determined by the planning computers used to configure the 
treatment and confirmed by MOSFET detectors placed within a mouth-guard at 
the sampling sites.  Samples produced RNA of suitable quality for analysis by 
qPCR.  Using 50 cGy dose as a threshold, 12 genes known to respond to 
radiation exposure were assessed.  Transcripts for HSPC132A, MDM2, PCNA, 
CDKN1A and CCNG1 were significantly elevated after exposure.  This study 
indicates the potential for buccal cavity transcript monitoring as a guide to 
radiation exposure.  However in terms of analysis, issues still remain in both the 
transient nature of transcript elevation and the biological significance of a positive 
result. 
 
To better address the complexity of the biological response to irradiation, an 
alternative approach was considered.  Many tumors, including those of the head 
and neck as well as breast and elsewhere, exhibit loss of heterozygosity (LOH) 
at chromosome11q23.  This location may be the site of one or more tumor 
suppressor genes.  LOH events are a known consequence of DNA double strand 
breaks and therefore, may be induced by irradiation.  Using a mucoepidermoid 
cell line (H292) as a model, cells were irradiated with either 4 or 8 Gy, and the 
surviving cells were passed through two rounds of cloning.  LOH at 11q23 was 
detected, using polymorphic markers for either the maternal or paternally derived 
chromosome that generated specific PCR products.  This experiment showed 
that 11q23 was highly susceptible to LOH after irradiation, with 10-20% of all 
irradiated clones showing LOH at 11q23, but not elsewhere on chromosome 11.  
This analysis has distinct advantages over conventional transcript or protein 
profiling.  First, the aberration is a marker linked to the transformation process.  
Second, the marker is open to rapid screening of affected cells, using PCR 
based techniques.  Third, the change is a permanent alteration in the genome 
(i.e., screening may be carried out on historically exposed individuals).  Finally, 
unaffected cells within the sampled region provide an appropriate internal control.  
Therefore, this approach measures an individual biological response. 
 
RADIATION BIOMARKERS AND TRIAGE---GENE EXPRESSION 
 
Biomarkers and applications from the DHS perspective were discussed by Dr. 
Sally Amundson (Columbia University).  In the event of a large-scale radiological 
incident, there would be a critical need for rapid, high-throughput radiation 
biodosimetry, both because of the need for medical triage, and as an active 
reassurance measure to decrease panic among those not actually exposed.  
Currently available biodosimetry approaches are not adequate for these needs, 
so some have suggested the development of gene expression profiles as a 
biodosimetry approach amenable to development of high-throughput and 
fieldable assays (34-36). 
 
Microarray analysis was previously used to identify 55 genes responding in 
human peripheral blood 24 hours after ex vivo exposure to γ-rays, and 
demonstrated linear induction of CDKN1A, DDB2 and XPC at doses from 0.2 to 
2 Gy at 24 and 48 hours after exposure (34).  Dose dependent increases in the 
expression of these genes were also detected at 4 and 72 hours post exposure, 
but exhibited less linearity.  In a later study, 85 genes responded in vivo in 
humans after the first or second 1.5 Gy fraction of total body irradiation (TBI), and 
showed dose-dependent increases of CDKN1A, DDB2, FCGR1A, and CXCL10 
through successive fractions (36). 
 
More recent studies have used the Agilent whole-genome microarray platform 
(37). Global gene expression profiles of ex vivo irradiated human peripheral 
blood from unrelated healthy donors were measured at several times after 
irradiation.  This study spanned a range of γ -ray doses relevant to medical 
decisions in a radiological triage situation, and identified hundreds of genes 
responding to radiation.  Quantitative real-time PCR of CDKN1A and other 
responding genes indicated a biphasic dose-response, quite similar to that seen 
previously in the ML-1 human myeloid cell line (38), with linear kinetics up to 2 
Gy and further increases with a decreased slope through 8 Gy.  There was also 
good agreement between gene induction using different irradiation and culture 
protocols, different donor pools, and different gene expression measurement 
techniques. 
 
In order to make such gene expression signatures useful for triage, a 
collaborative effort is underway to develop microfluidic cartridges (39) to take a 
blood sample and automatically perform a chemo-luminescence based gene-
expression assay.  The cartridges contain all necessary reagents, pumps, valves 
and control electronics, do not rely on molecular amplification methods such as 
PCR, and deliver highly consistent results (CV <10%).  A hand-held, 
microprocessor-controlled prototype has been developed for sample preparation, 
and a commercial chemo-luminescence reader is being modified for the 
microfluidic cartridges.  This biodosimetry concept was tested at the Coyote 
Crisis Campaign 2006, a disaster preparedness exercise in Scottsdale, Arizona. 
 
The standalone version of the microfluidic gene expression-profiling cartridge 
could potentially be adapted to provide rapid turnaround biodosimetry to support 
extended space exploration missions.  If, for instance, a solar particle event 
(SPE) occurred during a sortie on the lunar surface, rapidly available 
biodosimetric information could be used to help determine if an individual should 
be restricted to shielded areas for the remainder of the mission, or in extreme 
cases, if a mission should be cut short.  Targeted biodosimetry studies, such as 
characterizing the gene expression response to SPE spectrum protons, and 
validation at lower doses, would also be needed to establish the usefulness of 
such an approach. 
 
Additional studies are still needed to fully develop gene expression for any 
radiation biodosimetry application.  The in vivo responses must be more 
thoroughly characterized, including understanding to what extent the cancer 
patients undergoing TBI can be used as a model for healthy individuals.  Animal 
studies, such as some already performed in mice (40) or planned studies in non-
human primates, will also be critical.  Another very important area is determining 
the radiation specificity of the defined biodosimetry signatures.  Since a large 
proportion of the in vivo response to ionizing radiation comprises p53 regulated 
genes, and cytokines and genes involved in immune response (36), we need to 
be sure that infection, burns, general injury responses, or exposure to other 
toxins will not produce false positive radiation exposure signals.  The prototyped 
gene expression cassettes must also be thoroughly tested and their sensitivity 
and specificity determined.  Despite the remaining questions, current findings 
strongly support the usefulness of gene expression signatures and a biochip 
approach for radiation biodosimetry. 
 
RADIATION BIOMARKERS AND TRIAGE---MULTIPARAMETER 
APPROACHES 
 
William F. Blakely (USU/AFRRI) in his talk entitled: “Space Exploration 
Biodosimetry – Use of Integrated and Multiple Biomarkers” and co-authored by 
his Armed Forces Radiobiology Research Institute (AFRRI) colleagues, 
illustrated the potential dual-use of AFRRI’s integrated biodosimetry for space 
flight biodosimetry. Using a scenario of a radiation exposure during a Mars 
mission, Dr. Blakely showed how dynamic, space-flight deployable (41), and 
integrated multiparameter biodosimetry can provide key contributions in the 
medical management of acute-radiation sickness (ARS) injuries. He 
recommended deployment of these or alternative software applications and 
consideration for use of blood cell counters and radiation-responsive protein 
bioassays for use on long-duration and other space flight missions where 
radiation over-exposures risks are possible. 
 
Effective medical management of suspected radiation exposure incidents 
requires the measurement of dynamic medical data and physical dosimetry in 
order to provide diagnostic information to the treating physician and dose 
assessment for personnel radiation protection records.  The accepted generic 
multiparameter and early-response approach includes observing prodromal signs 
and symptoms; obtaining complete blood counts with white blood cell differential; 
measuring radioactivity and monitoring the exposed individual; bioassay 
sampling, if appropriate, to determine radioactivity contamination; sampling blood 
for the chromosome-aberration cytogenetic bioassay using the “gold standard” 
dicentric assay for dose assessment; and using other available dosimetry 
approaches. AFRRI’s Biodosimetry Assessment Tool (BAT) is a comprehensive 
software application developed for recording diagnostic information in suspected 
radiological exposures (42).  AFRRI is also developing a First-responder 
Radiological Assessment Triage (FRAT), for use on hand-held personal digital 
assistant devices, that provides data collection templates and ability to integrate 
results for analysis of clinical signs and symptoms, lymphocyte counts, physical 
dosimetry, radioactivity, and location-based dose estimates (43). 
 
Identification and validation of early-phase radiation biomarkers are needed to 
provide enhancement in biological dosimetry capability to assess individuals 
suspected of exposure to ionizing radiation (44).  This need is of great 
importance to provide quantitative indications for early initiation (20-h after 
radiation exposure) of cytokine therapy in individuals exposed to life-threatening 
radiation doses as well as to provide effective triage tools for first-responders in 
mass-casualty radiological incidents (45).  Monitoring of radiation exposure by 
biological dosimetry systems is complimentary to physical dosimetry, since they 
can weigh radiation quality and dose rate according to biological efficacy.  
Molecular biomarkers are used as diagnostic endpoints in environmental health 
and cancer. Hofmann and colleagues (46) reported radiation-induced increases 
of serum amylase in 41 patients following either whole-body irradiation or 
irradiation of the head and neck region.  Mal’tsev and colleagues (47) measured 
serum C-reactive protein (CRP) in Chernobyl radiation victims within 1-9 days 
after exposure and correlated its levels to ARS severity.  Dr. Blakely’s research 
group’s working hypothesis is that hematological changes, gene expression, and 
encoded protein biomarkers detected in biological samples (peripheral blood) 
can: a) distinguish the concerned public from individuals exposed to radiation 
and b) triage exposed individuals by assessing radiation dose and injury.  Their 
research strategy involves use of both ex vivo (human) and in vivo (murine, non-
human primate) radiation model systems.  They have employed quantitative 
methodology to measure changes in blood cell (e.g., lymphocytes, neutrophils, 
etc.) counts, multiple gene-expression and encoded-protein targets as well as 
blood serum enzyme activities.  Blood cell counts were measured using a clinical 
hematology analyzer.  Gene expression targets (Gadd45a, Ddb2, Bax, Bcl-2, 
CDKN1A [p21WafCip]) were quantified by real-time reverse-transcriptase 
polymerase-chain-reaction (RT-PCR) bioassay (48,49).  Encoded proteins (ras 
p21, raf, Gadd45a, Bax, Bcl-2, p21WafCip, IL-6, CRP) were detected by the 
enzyme-linked immunosorbent and microsphere (LuminexTM)-based assays 
(41,50).  Blood serum levels of amylase activity were measured using 
conventional commercial reagents used in blood chemistry analyzers (42).  
Radiation-induced changes in peripheral blood cell counts as well as up-
regulation of gene expression and protein targets from varied pathways (DNA 
damage and repair, cell-cycle checkpoints, apoptosis/anti-apoptosis, cytokine, 
etc.) and radiosensitive tissue (salivary gland) from selected radiation model 
systems will be presented (41,48,49-51).  These results support the proof-of-
concept that use of multiple early-response biomarkers can provide useful 
diagnostic indices for medical management of radiation casualties. 
 
ADVANCES IN WHOLE GENOME TILING ARRAYS 
 
Dr. Viktor Stolc (NASA Ames Research Center) discussed the cutting-edge 
genomics capabilities of the Ames Genome Research Facility 
(http://phenomorph.arc.nasa.gov/) and their recent work on high-density 
oligonucleotide tiling arrays.  Identification of the transcribed regions in model 
organisms as well as the human genome is one of the major challenges of 
postgenomic biology for understanding human physiology.  Empirical 
transcriptome mapping, using whole-genome tiling microarrays has been shown 
to be the most comprehensive and unbiased approach. This novel method uses 
high-density oligonucleotide microarrays with probes chosen uniformly from both 
strands of the entire genomes including all gene-coding and intergenic regions.  
By hybridizing the microarrays with tissue specific or pooled total RNA samples, 
a genome-wide picture of transcription can be derived.  The comprehensive 
transcriptome analysis enables identification of the genetic basis of biological 
phenotypes and revealed transcribed sequences not detected by other methods. 
Advancement of microarray design to enable probing of polygenetic samples will 
significantly improve medical diagnostics and efficacy of treatment in human 
diseases. 
 
Comprehensive genome-wide analysis of transcription can be performed rapidly 
with high-density oligonucleotide microarrays designed to encode unique 
sequences that hybridize only to their intended complement RNA sequences. 
Significant computational resources are required to compute all possible 
sequence variants for the microarray design.  The NASA Ames Genome 
Research Facility, in collaboration with several academic laboratories produced 
optimized specificity and sensitivity of the oligonucleotide probes for detection 
and discrimination of very low abundance transcripts (52-55).  For example, in 
the sea urchin embryo, they were able to detect and discriminate the differential 
expression of very low abundance RNA transcripts even for genes known to be 
expressed at low levels in only a few cells (52).  Dr. Stolc stated that a recently 
completed high-resolution map of the mouse transcriptome produced using the 
same technique that they applied to map the human genome (53), and the sea 
urchin embryo (52), revealed significant regions of novel RNA expression that 
are syntenous between the mouse and human genomes.  This comparative 
analysis also resulted in identification of short transcribed regions in the human 
genome, previously undetected solely from the human data due to lower 
statistical significance.  Thousands of previously uncharacterized transcripts in 
the mouse genome enabled identification of several hundred previously un-
described human transcripts (55).   
 
ADVANCES IN MASS SPECTROMETRY PROTEOMICS 
Dr. Julie Leary (University of California, Davis) provided an overview of the state-
of-the-art in mass spectrometry (MS) proteomics analysis.  Mass spectrometric 
data from proteomics analysis were presented of both large molecular clusters 
and small peptides from proteins containing post-translational modifications 
(56,57).  New developments involving organic derivatizing agents can be used to 
unambiguously determine the sites of post-translational sulfation on proteins and 
peptides (56).  In a somewhat related fashion, metal affinity columns are 
extremely successful enriching proteins and peptides containing low level 
phosphorylation (57).  Since phosphorylation and sulfation are isobaric, this 
combination of solution sample preparation and mass spectrometry can be 
paramount in distinguishing these important changes. 
 Mass Spectrometry technology can be very effective for the analysis of various 
biomarkers, particularly peptides and proteins.  Modern advances in this field 
have now produced instrumentation that is capable of analyzing large molecular 
weight (megadalton) multi-subunit architecture.  This can be very powerful for 
investigating how proteins interact in both normal and diseased tissue as well as 
measuring stoichiometric changes to these proteins during radiation exposure.  
One can easily envision isolating protein biomarkers from serum samples of 
exposed individuals and tracking both the various post-translational modifications 
that may differ, as well as comparison and contrast of proteins and peptides that 
may differ from exposed and non-exposed individuals. 
 
RADIATION BIODOSIMETRY FOR ESTIMATION OF CANCER RISK IN A RAT 
SKIN MODEL 
Dr. Fredric Burns (New York University) presented his work on radiation 
biodosimetry of cancer induction in rat skin.  DNA double strand breaks (DSBs) 
have potential relevance to carcinogenesis because of the tendency that such 
breaks join, most frequently by non-homologous end joining, to create 
chromosome rearrangements and elevated genomic instability (58-61).  Although 
DSBs occur spontaneously, their highly efficient induction by ionizing radiation is 
probably unique among carcinogenic agents (62).  DSBs are also strongly linked 
to the cytotoxic action of ionizing radiation which competes with carcinogenesis, 
particularly at higher radiation doses (63,64). 
 Radiation ionizations occur either within dense tracks (if the incident ion is heavy) 
or scattered randomly (if the incident particle is light). As LET increases in dense 
tracks, DSB joinings become more numerous because of the lower average 
distance between DSBs. For randomly distributed DSBs joinings increase with 
radiation dose to the power of 2, because each DSB is produced in proportion to 
radiation dose. The above considerations lead to an expression describing the 
expected yield of DSB joinings for any type of radiation as follows:  
                                 Yield(D,L) = CLD + BD2                             (Equation A),  
where L = LET, D = radiation dose and B and C are to be evaluated empirically. 
Equation A is the well-known linear-quadratic function, except for the L in the 
linear term.  
 
While it is plausible that Equation A might correctly describe the yield of DSB 
joinings, a leap is required to imagine that this same functional form might also 
be applicable to cancer induction. Surely the extensive genomic alterations 
associated with cancer progression would obliterate all traces of any initial DNA 
damage with causative relevance to the cancers.  But what if Equation A fits both 
cancer and DSB joining yields across a broad range of LETs and doses? 
Wouldn’t that be a contradiction of initial lesion obliteration and raise the 
possibility that DSB joinings are the long-sought, causative DNA alterations of 
radiation carcinogenesis?  At present, the latter is an unproven postulate in any 
other organ or species, but in rat skin it appears to be well-founded based on 
carcinoma yields and estimates of DSBs joinings in surrogate keratinocytes. One 
explanation how Equation A could explain both cancer and DSB induction would 
be that the cancers originate in a small fraction of irradiated cells most probably 
stem cells with just the right joining that permits long-term survival with elevated 
levels of genomic instability. It is the latter that eventually produces the additional 
genomic alterations required for malignancy. 
 
As surrogates for rat keratinocytes in vivo, rat skin keratinocytes were irradiated 
with either 56Fe ions (L = 125 keV/µ), x-rays (L = ~0.4 keV/µ) or protons (L = 25 
keV/µ) and DSBs were quantified by means of the in situ γ-H2AX antibody 
technique.  The results for 56Fe ions showed that many DSBs (H2AX-positive 
foci) were aligned along straight, parallel tracks oriented in the beam direction for 
at least 4 h after exposure. Interestingly, straight tracks persisted in parallel 
formation as nuclei rotated slowly relative to their orientation at time zero.   The γ-
H2AX antibody technique provides a way to estimate the yield of DSB joinings so 
that quantitative comparisons with cancer yields for the same doses and 
radiation types become possible.  The linear term in the DSB version of Equation 
A was estimated based on total DSBs per track for the 3 radiation types studied 
as follows: 2 doses (1.5 and 3.0 Gy) of 56Fe ions, roughly equicarcinogenic doses 
(4.5 and 9.0 Gy) of x-rays and Bragg peak protons (0.3 and 1.1 Gy).  Of course 
at higher doses every epithelial cell is expected to exhibit multiple DSBs, while 
the cancer probability is only on the order of 1 per 106 cells exposed.  It is an 
advantage for biodosimetric purposes that DSBs are very frequent in comparison 
to the cancers, but proportionality between the 2 endpoints must be verified 
empirically throughout dose and LET ranges typical of space radiation.  
 
When DSB joinings in surrogate keratinocytes and skin cancer yields for 3 
diverse LET values were plotted as a function of radiation dose an almost exact 
superimposition was apparent when proportionality was fixed at 100 DSBs per 
keratinocyte = 1.0 carcinoma per rat at 1 year.  A plot of the cancer and DSB 
yields on the same coordinates showed cancer yields falling within the error bars 
of the DSB estimates at all 6 available dose points.  If both DSBs and cancers 
show dose and LET dependencies as described by Equation A, a useful tool for 
predicting carcinogenic outcomes of various, possibly even complex, radiation 
exposure scenarios might become available on the basis of a comparatively 
simple short-term in vitro assay.   
 
CONFOUNDING FACTORS 
 
Dr. Terry C. Pellmar (Armed Forces Radiobiology Research Institute) discussed 
factors that may confound biomarker analyses following radiation exposure.  
Many factors influence biodosimetric assessments.  Dose- and time- 
dependence of a biomarker are clearly characteristics that must be addressed for 
accurate biodosimetry.  While some biomarkers might increase throughout the 
radiation dose range of interest, others might level off or even begin to decrease 
as dose goes up.  Time of sampling can significantly impact measurements, as 
well (41).  Some markers increase slowly and are sustained; others increase 
quickly but only transiently.  Quality of radiation also impacts the dose response 
curve for biomarkers.  For example, the calibration curves for cytogenetic 
biodosimetry using dicentrics show that fission neutrons are more effective than 
gamma rays for an equivalent absorbed dose (65).  Accurate interpretation of the 
assay requires information on radiation quality.  In addition, the possibility of 
partial body exposure needs to be considered.  High radiation doses to small 
areas may not be revealed by a biomarker that reflects whole body changes.  
Differentiation of partial-body from total-body exposures will be important for 
treatment decisions. 
 
The specificity of a biomarker and the variability within the population must also 
be considered in development of biodosimetric assays.  For example, the 
prodromal symptoms, nausea and vomiting, are excellent indicators of radiation 
exposure but are symptoms of other common conditions.  In addition, the inter-
individual variability in the emetic response to radiation is large (66).  Some 
people may vomit early to a relatively low dose while others may not vomit at all, 
despite a serious exposure.  Biomarkers that respond robustly to radiation may 
also respond to other conditions.  Baseline levels of the biomarkers may be 
widely disparate in the population, making small changes difficult to discern (43).  
Changes in biomarkers may be altered by the health status of an individual and 
by any drugs that have been taken (36).  Furthermore any injuries that occur in 
addition to the radiation exposure could have an impact on biomarker levels. 
 Biomarkers are very useful in defining a radiation exposure but many 
confounding factors exist that must be considered in their interpretation. 
 
DISCUSSION AND CONCLUSIONS 
 
The workshop presentations stimulated the following discussion and conclusions. 
 
Cytogenetic analyses in peripheral blood lymphocytes have been used to 
reconstruct radiation dose to astronauts in space (e.g., see 4-9). Although 
physical radiation monitoring is employed on all human missions in space---and 
more sophisticated technologies will be available for return to the Moon—the 
advantage of biomarkers is measurement of the biological response in the 
individual, which includes contribution from dose, dose rate, radiation quality, and 
biologically-based modifiers of response such as DNA repair.  Hence, biomarkers 
provide a measurement that would be expected to correlate better with health 
outcome than a physical dosimeter alone.  An accurate biomarker (biodosimeter) 
response could be critical for treatment management if an astronaut has received 
a large acute exposure from a SPE. 
 
It would be particularly helpful for long-duration human space exploration to have 
biomarkers that measure individual susceptibility to the major health risks 
associated with radiation exposure in space--- carcinogenesis, acute and late 
CNS risks, chronic and degenerative tissue risks, and acute radiation risks (2).  
Such markers may be used, for example, to select astronauts for long-duration 
missions who may have low susceptibility to the major radiation-induced health 
risks.  The risk that can be estimated presently from biomarkers (biodosimetry) is 
related to average population risk, not individual risk, and can therefore not be 
used to select resistant individuals.  However, available biomarkers can be used 
to identify individuals with unusually high radiosensitivity, such as those with 
certain known DNA repair deficiencies.  
 
Astronaut biodosimetry and biomarker evaluations would be aided by relatively 
few individuals on a space mission and the ability to obtain pre and post samples 
(and perhaps during mission samples on very long missions).  However, these 
advantages are tempered by possible confounding factors. For long-duration 
missions, the temporal stability of the biomarker would be particularly important.  
Temporal instability can result from both biological and physical factors. In the 
case of a lunar mission, during a large SPE, when an accurate biodose may be 
most urgently needed, the SPE proton dose will be highly skewed toward the first 
couple of cm of tissue due to the low proton energies.  This inhomogeneous dose 
distribution will tend to result in (a) reduced initial biomarker frequency (as 
compared with uniform whole-body dose) due to dilution with unirradiated 
biomarkers in more shielded body compartments (this phenomenon is clearly 
observed in partial-body exposures), and (b) variable time course profiles of 
changes in transitory radiation-responsive biomarker concentration over time due 
to differential stem cell doses.  Importantly, this would be the case even for 
biomarkers that are stable following uniform whole body dose (67). 
 
Given that most individuals show extensive sequence variation in their DNA 
repair genes, it is likely that susceptibility will vary between individuals depending 
on the particular combination of alleles inherited.  For example, mice 
heterozygous for a mutation in ATM have heightened susceptibility to cancer and 
are more sensitive to ionizing radiation.  However, other factors may cause 
increased or decreased sensitivity to radiation (e.g., allelic imbalance in gene 
expression). 
 
Systems biology approaches are showing substantial promise for improving the 
molecular understanding of the early cellular responses to low-dose radiation and 
to help to reduce the uncertainty of assessing risk at low-dose levels.  The finding 
of low-dose unique genes and pathways in both human cells and mouse brain 
tissues sets the foundation for identifying risk predictors for genomic instability 
and disease susceptibility in tissues irradiated in vivo. 
 
While DNA microarray analysis may provide insight into gene function within and 
across biological networks, meaningful data can be generated only when studies 
are appropriately controlled and when the state of a living system is well defined.  
Since there is no consensus regarding the best method to analyze a multivariate 
data set, it is important that microarray data be submitted to public databases 
where information can be reevaluated and interpreted, as new methods for data 
analysis are applied. 
 
Additional studies are needed to fully develop gene expression for any radiation 
biodosimetry application.  The in vivo responses must be more thoroughly 
characterized, including understanding to what extent the cancer patients can be 
used as a model for healthy individuals.  Animal studies will also be critical. Also, 
since a large proportion of the in vivo response to ionizing radiation comprises 
p53 regulated genes, and cytokines and genes involved in immune response 
(29), we need to be sure that infection, burns, general injury responses, or 
exposure to other toxins will not produce false positive radiation exposure 
signals. 
 
Studies in support of biodefense programs clearly illustrate the normal variability 
in both gene expression and proteins, and demonstrate the need for multiple 
simultaneous markers.  Multiple early-response biomarkers can also provide 
useful diagnostic indices for medical management of radiation casualties.  
Results from studies in rat skin carcinogenesis indicate that enumeration of 
DSBs in surrogate cells in vitro may, when properly calibrated, become a 
biodosimetric tool for estimating cancer risks associated with space radiation. 
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